Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvajal, Richard D., Butler, Marcus O., Shoushtari, Alexander N., Hassel, Jessica C., Ikeguchi, Alexandra, Hernandez-Aya, Leonel, Nathan, Paul, Hamid, Omid, Piulats, Josep M., Rioth, Matthew, Johnson, Douglas B., Luke, Jason J., Espinosa, Enrique, Leyvraz, Serge, Collins, Laura, Goodall, Howard M., Ranade, Koustubh, Holland, Chris, Abdullah, Shaad E., Sacco, Joseph J., Sato, Takami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671803/
https://www.ncbi.nlm.nih.gov/pubmed/36229663
http://dx.doi.org/10.1038/s41591-022-02015-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671803/
https://www.ncbi.nlm.nih.gov/pubmed/36229663
http://dx.doi.org/10.1038/s41591-022-02015-7

Ejemplares similares